Physician profile
Anthony J Jaslowski
NPI 1467546507
$1,489.75
in general payments reported to CMS, 2019-2025
23 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $12.45 · 2021: $11.92 · 2022: $240 · 2023: $252 · 2024: $406 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $426.51 | 2024-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $200.81 | 2019 | |
| Adc Therapeutics America, INC. | $175.66 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $121.29 | 2020-2022 | |
| Immunogen, INC. | $117.30 | 2023 | Elahere |
| Kite Pharma, INC. | $110.43 | 2023 | |
| Janssen Scientific Affairs, LLC | $92.10 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Sobi, INC | $88.56 | 2025 | |
| Janssen Biotech, INC. | $37.20 | 2019 | |
| Incyte Corporation | $24.33 | 2023 | Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $23.67 | 2022 | |
| Genentech, INC. | $22.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Jaslowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.